A Pilot Study of Thalidomide to Overcome Lenalidomide Resistance in Patients Suffering Biochemical Progression on Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 30 Apr 2019
Price : $35 *
At a glance
- Drugs Thalidomide (Primary) ; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 23 Nov 2016 Status changed from active, no longer recruiting to discontinued.
- 03 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 19 Apr 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.